Shanghai Bio-heart Biological Technology Co., Ltd. (HKG:2185)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.870
-0.110 (-3.69%)
Jul 10, 2026, 1:55 PM HKT
Market Cap725.38M -25.5%
Revenue (ttm)50.00M
Net Income-77.96M
EPS-0.32
Shares Out 243.42M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume67,400
Open2.960
Previous Close2.980
Day's Range2.770 - 3.020
52-Week Range1.820 - 10.770
Beta0.10
Analystsn/a
Price Targetn/a
Earnings DateAug 11, 2026

About HKG:2185

Shanghai Bio-heart Biological Technology Co., Ltd., together with its subsidiaries, engages in the research, development, and commercialization of invasive treatment products in China. The company develops Bioheart, a bioresorbable scaffolds system, which is in registration stage for percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis, a renal denervation system, which is in clinical stage for the treatment of uncontrolled hypertension and resistant hypertension; and DCB, a sirolimus drug coated ba... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 65
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2185
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements